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Background: Advanced oxidation protein products (AOPP) are newly identified efficient oxidative stress biomarkers.
In a longitudinal birth cohort the effects were investigated of genetic polymorphisms in five oxidative pathway
genes on AOPP levels.
Methods: This study is part of a three-arm randomized, double-blind, placebo-controlled trial. Three hundred and
twelve children were included in the present study with AOPP levels measured at 2.5, 5.5, 10.5, 15 and 24 months
of age. Twelve polymorphisms were genotyped in five oxidative stress pathway genes: glutathione reductase (GSR),
glutamylcysteine synthetase (GCLC), glutathione S-transferase (GST) P1, haem oxygenase 1 (HMOX1) and superoxide
dismutase 2 (SOD2) in 298 children. There were 284 children assessed for anaemia and clinical malaria infection at
the age of 24 months.
Results: Two principal components (PCA1 and PCA2) were derived from the AOPP levels measured at the five
time points. PCA1 was significantly associated with anaemia (p = 0.0002), and PCA2 with clinical malaria infection
(p = 0.047). In the K-Means Cluster Analysis based on levels of AOPP, children were clustered into two groups: Group
A (lower AOPP levels) and Group B (higher AOPP levels). The cluster membership was significantly associated with
anaemia (p =0.003) as well as with the GSR RS3594 polymorphism (p = 0.037). Mixed linear regression analyses
found that the single nucleotide polymorphisms GCLC RS10948751 and HMOX1 RS17885925 were significantly
associated with AOPP levels (p = 0.030 and p = 0.027, respectively).
Conclusion: Plasma AOPP levels were predictive for anaemia and oxidative stress markers for clinical malaria
infection in two year old children. Several polymorphisms in GCLC, GSR and HMOX1 genes were associated with
oxidative stress status of these children.
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Oxidative stress is a common pathogenic mechanism
underlying the development of many diseases and condi-
tions including malaria infection, in which both the host
and the parasite are under its effects. Adapting to the
oxidative stress exerted by the host immune response
against malaria infection, Plasmodium falciparum has
developed an elaborate reduction-oxidation (redox) sys-
tem to maintain adequate antioxidant defence through-
out its complex life cycle [1]. In humans, oxidative
changes resulting from malaria infection are central to
the host protective response against the malaria parasite,
and to some of the pathophysiology associated with clin-
ical malaria infection. Enhanced oxidative stress reduces
erythrocyte deformability [2,3], contributing to haemoly-
sis, and the development of anaemia [4]. Although oxi-
dative stress, anaemia and malaria infection are closely
related in their pathogenic mechanisms, their complex
relationships and the functional relevance of oxidative
stress genes are poorly understood.
Oxidative pathway genes have been extensively investi-
gated for associations with different phenotypes for their
anti-oxidative effects on a range of conditions and diseases
[5,6]. Genetic variants in glutathione S-transferase (GST)
genes have been reported to be associated with susceptibil-
ity to many chronic inflammatory conditions and other dis-
eases including malaria [7,8], anaemia [9], asthma [10],
allergy [10], chronic obstructive pulmonary disease (COPD)
[11], diabetes [12], cardiovascular diseases [12] and cancer
[13]. Glutathione reductase (GSR) is also central to cellular
antioxidant defence as it reduces oxidized glutathione
disulphide (GSSG) to the sulfhydryl form GSH. Glutamate
cysteine ligase, also known as gamma-glutamylcysteine
synthetase, has a heavy catalytic subunit (GCLC) and is the
rate limiting enzyme of glutathione synthesis that plays a
crucial role in the intracellular antioxidant defence system.
Haem oxygenase 1 (HMOX1), which degrades haem into
biliverdin, carbon monoxide and free iron, is an essential
enzyme in haem catabolism and protects against oxidative
tissue damage. Superoxide dismutase 2 (SOD2) is also
an important intracellular antioxidant enzyme. Numerous
studies have reported on associations of the genetic vari-
ants in GSR [11], GCLC [14,15], HMOX1 [16] and SOD2
[17] with oxidative stress related disorders and conditions
including malaria [16,18,19].
Evidence of oxidative stress, or an antioxidant status, is
usually assessed using biomarkers that reflect the actual
oxidative stress in a tissue or the whole body. Plasma pro-
teins, predominantly albumin and fibrinogen, undergo
molecular modifications by oxidation which can be mea-
sured as advanced oxidation protein products (AOPP),
which were first identified by Witko-Sarsat et al. as effi-
cient oxidative stress biomarkers in uraemic patients
[20,21]. Further studies confirmed AOPP concentrationsas inflammatory markers in several diseases [22,23], but
there is no report of any investigation on AOPP in malaria
infection prior to this study.
In the AgeMal (Age of exposure and immunity to mal-
aria in infants) collaborative study (ClinicalTrials.gov
identifier NCT00231452), the genetic effects were inves-
tigated in young children of 12 functionally important
polymorphisms in five oxidative pathway genes regard-
ing their functional relevance for oxidative stress status
measured as AOPP levels, as well as for the two pheno-
types of anaemia and clinical malaria infection. Genetic
variants in GCLC and HMOX1 were associated with
AOPP concentrations measured at five time points in
the first two years of life. The AOPP biomarker was as-
sociated with anaemia and clinical malaria infection
ascertained at two years of age. There is evidence that
oxidative stress pathway genes contribute to the balance
between a pro- and anti-oxidant status that is related to
the development of anaemia and clinical malaria infec-
tion in young children.
Methods
Study population
This study is part of the AgeMal project consisting of a
three-arm randomized, double-blind, placebo-controlled
trial aimed at determining the importance of time of
exposure to P. falciparum during the first year of life
for the development of naturally acquired immunity
[24]. The study was conducted in the Manhiça District,
Maputo Province, in southern Mozambique, where
transmission of P. falciparum is perennial with marked
seasonality and moderate intensity, and the entomo-
logical inoculation rate of 38 infective bites/person/year
[25]. The study population has been previously described
[24,26,27]. Briefly, HIV-negative pregnant women were
recruited during the third trimester of pregnancy and
written informed consent was sought to enrol their new-
born children in the study. The controlled exposure to
P. falciparum infection was fulfilled with different proto-
cols for administration of monthly chemoprophylaxis
with sulphadoxine-pyrimethamine plus artesunate to the
children during the first year of life in a three-arm inter-
vention trial. A total of 312 infants were included in the
study, with AOPP measured at 2.5, 5.5, 10.5, 15 and
24 months of age, and > 88% of children analysed at each
of the five time points. There were 284 children who
had their anaemia and clinical malaria infection status
determined at the age of 24 months, and DNA samples
were available from 298 children. The study was ap-
proved by the National Mozambican Ethics Committee,
the Hospital Clínic of Barcelona Ethics Review Commit-
tee, the Bioethical Committee of the Torino University
School of Medicine, and the Princess Margaret Hospital
for Children Ethics Committee (1473/EP) in Perth.
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Genomic DNA was extracted from peripheral blood
mononuclear cells by an automated DNA extraction in-
strument (Autopure LS; QIAGEN, Hilden, Germany).
Genetic polymorphisms were selected from the five oxida-
tive stress pathway genes: GSR, GCLC, GST P1, HMOX1
and SOD2 based on their potential functional importance
and estimated minor allele frequency (>10%) in Africans.
Two single nucleotide polymorphisms (SNPs) were geno-
typed in GSR, 3 in GCLC, 3 in GST P1, 2 SNPs and 1 AG
deletion in HMOX1, and 1 SNP in SOD2. The genomic lo-
cations of these polymorphisms in the five genes are
shown in Additional file 1. Genotyping of the 11 SNPs
and 1 deletion was performed by the Australian Genome
Research Facility using the iPLEX assay on the MassAR-
RAY system (Sequenom, San Diego, CA) [28] according to
the manufacturer’s instructions.
Measurement of AOPP concentration in plasma
Spectrophotometric determination of AOPP plasma levels
was performed by modification of the Witko-Sarsat’s
method in a micro-plate reader [20,29]. Briefly, 200 μl of
plasma diluted 1:10 in PBS and chloramine-T standard
samples (0-100 μmol/l) were pipetted into a 96-well UV-
transparent plate. Eight μl of 1.16 M KI were added to
each standard well, followed by 30 μl of acetic acid added
two minutes later. The absorbance read at 340 nm against
a blank was referred to the standard absorbance. AOPP
concentrations were expressed as μmol/l of plasma.
Definitions of anaemia and clinical malaria infection
A clinical malaria episode was defined as axillary
temperature ≥ 37.5°C, or history of fever within the prior
24 h, plus the presence in peripheral blood of P. falcip-
arum asexual stage parasites of any density, determined by
microscopy following standard quality control procedures
[24]. Anaemia was defined as haemoglobin (Hb) < 8 g/dl
or packed cell volume (PCV) < 25% (if Hb results were not
available), which corresponds to a moderate to severe
degree of anaemia.
Statistical analysis
For the 12 polymorphisms in the five oxidative stress
pathway genes, Hardy-Weinberg equilibrium was exam-
ined using the online tool [30]. The levels of AOPP at the
five time points (2.5, 5.5, 10.5, 15 and 24 months of age)
were log transformed to have an approximately normal
distribution. Principal component analysis (PCA), which
can find a linear combination of variables and in which
the combination variables accounts for as much variation
in the original variables as possible, was employed to com-
pute the component scores for AOPP levels at the five
time points. K-Means Cluster Analysis was used to inves-
tigate the cluster membership of individual children basedon levels of AOPP at the five time points. Children were
clustered into two groups: Group A (lower AOPP levels)
and Group B (higher AOPP levels).
The associations between genotypes and PCA scores
of AOPP levels were investigated using analysis of vari-
ance and independent sample t test, when appropriate.
The associations of PCA scores of AOPP levels were
also investigated with cluster membership, anaemia and
clinical malaria infection at the age of 24 months using
independent sample t tests. Chi-square tests were employed
to investigate the associations of genotypes, anaemia, and
malaria infection with cluster membership. A mixed linear
regression model was further employed to investigate the
associations of genotypes with levels of AOPP adjusting for
gender and presence/absence of anaemia. Other potential
confounding factors were investigated for their association
with levels of AOPP. Analyses were conducted using SPSS
(PASW Statistics 18). All p-values are two-sided and were
considered significant when <0.05.
Results
Genotypes
Eleven single nucleotide and 1 insertion/deletion polymor-
phisms were genotyped in five functionally important oxi-
dative stress pathway genes in 298 young children. Table 1
shows the frequencies of the polymorphisms in these
genes. The insertion/deletion variant of RS17883725 in
HMOX1 was not in Hardy-Weinberg Equilibrium so it
was excluded from further analyses. There was also
complete linkage disequilibrium for the RS10948751 and
RS7742367 SNPs in the GCLC gene, therefore, only
RS10948751 was included in further analyses.
Plasma AOPP
Plasma AOPP levels were measured in 302 children at
2.5 months, 300 at 5.5 months, 296 at 10.5 months, 283
at 15 months and 274 at 24 months of age, showing de-
creasing levels by age (Table 2). 235 children had plasma
AOPP measured at all five time points.
Factor and cluster analysis on plasma AOPP levels
Using PCA two components were derived that explained
50% of the variation of plasma AOPP levels at the five
points. The levels of AOPP at the first four time points
(2.5, 5.5, 10.5 and 15 months of age) significantly and posi-
tively contributed to the first component score (PCA1)
that accounted for 30% of the variation of plasma AOPP
levels at the five time points. The levels of AOPP at
24 months of age significantly and positively contributed
to the second component score (PCA2) that accounted
for 20% of the variation of the plasma AOPP levels at the
five time points. In addition, the levels of AOPP at 2.5 and
5.5 months of age negatively contributed to the PCA2.
Then, the PCA1 was related to plasma AOPP levels before
Table 1 Frequencies of the 12 polymorphisms in the five
oxidative pathway genes
Genotypes n % MAF HWE
GSR
RS1002149(G/T)
GG 159 55.0 24.6 0.11
GT 118 40.8
TT 12 4.2
RS3594 (C/A)
CC 243 82.1 9.5 0.73
CA 50 16.9
AA 3 1.0
GCLC
RS10948751 (A/C)
AA 104 35.6 40.6 0.81
CA 139 47.6
CC 49 16.8
RS1901773 (G/C)
GG 69 25.6 48.1 0.46
CG 142 52.6
CC 59 21.9
RS7742367 (T/C)
TT 100 35.7 40.7 0.71
CT 132 47.1
CC 48 17.1
GSTP1
RS1695 (A/G)
AA 81 28.0 47.4 0.81
AG 142 49.1
GG 66 22.8
RS17593068 (T/G)
TT 79 28.0 49.1 0.15
TG 129 45.7
GG 74 26.2
RS6591256 (A/G)
AA 77 26.6 48.3 1.0
AG 146 50.3
GG 67 23.1
HMOX1
RS11555832 (T/C)
TT 107 37.4 0.40 0.31
CT 129 45.1
CC 50 17.5
RS17883725 (AG/DEL)
AG 81 29.2 49.5 0.02
Table 1 Frequencies of the 12 polymorphisms in the five
oxidative pathway genes (Continued)
AG.DEL 118 42.6
DEL.DEL 78 28.2
RS17885925 (T/C)
TT 275 92.3 3.9 1.0
CT 23 7.7
SOD2
RS4880 (T/C)
TT 95 32.3 42.3 0.55
CT 149 50.7
CC 50 17.0
MAF Minor Allele Frequency.
HWE Hardy-Weinberg Equilibrium.
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with plasma AOPP levels at 24 months of age and nega-
tively correlated with plasma AOPP levels in infants less
than 6 months of age. Additional file 1 shows the two
component matrix with the plasma AOPP levels at the
five time points.
Based on the levels of AOPP at the five time points,
the children were clustered into two groups: Group A
(lower AOPP levels) and Group B (higher AOPP levels).
Group A included 161 children and Group B included
151 children. It was expected that the cluster member-
ship would be associated with the levels of AOPP at
the five time points as well as to the two PCA compo-
nents, as the membership was defined from the levels of
AOPP. Figure 1 shows the differences in the levels of
AOPP (Figure 1A) and in the two principal components
(Figure 1B) between children in Group A and Group B.
Children in Group A had consistently and significantly
lower levels of AOPP at the five time points, and lower
scores of PCA1 (p < 0.0001).
Anaemia and clinical malaria infection at 24 months of age
Among the 284 children who were followed up to the
age of 24 months, 23 (8.1%) had anaemia and 32 (11.3%)
had clinical malaria infection at this last time point.Table 2 Levels of AOPP by cross-section
Months
of age
n GM
(μmol/L)
95% CI
Lower Upper
2.5 302 352.4 329.5 376.8
5.5 300 263.9 245.4 283.9
10.5 296 207.5 192.3 223.9
15 283 154.0 141.6 167.5
24 274 104.2 96.8 112.1
GM Geometric mean.
CI Confidence Interval.
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Figure 1 AOPP levels at the five time points and PCA scores stratified by cluster membership. A: AOPP levels (geometric mean and 95%
confidence intervals) at the five time points; B: PCA scores; Cluster membership was clarified using K-Means Cluster Analysis.
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higher levels of plasma AOPP at all five time points,
with significant differences at ages 2.5 months (p = 0.014)
and 15 months (p = 0.001) (Figure 2A). Children with an-
aemia at 24 months had significantly higher PCA1 scores
(p = 0.0002), but not higher PCA2 (Figure 2B). Children
with clinical malaria infection at age 24 months did not
have significantly higher AOPP levels at ages 2.5, 5.5, 10.5
and 15 months, but had significantly higher AOPP levels
at 24 months (Figure 3A). Clinical malaria infection at age
24 months did not associate with PCA1, but was signifi-
cantly associated with an increased PCA2 (p = 0.047)
(Figure 3B).
The associations of the cluster membership were also
investigated with anaemia and clinical malaria infection
at age 24 months. Children in Group A, that had lower
levels of AOPP, had a significantly lower prevalence of
anaemia compared with those in Group B (3.4% vs.Le
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Figure 2 AOPP levels at the five time points and PCA scores (mean an
A: AOPP levels (geometric mean and 95% confidence intervals) at the five
intervals); Anaemia was defined at age two years.13.0%, p = 0.003). The odds ratio of B membership for
anaemia was 4.23 (95% confidence interval: 1.53 - 11.7).
No association was found between cluster membership
and clinical malaria infection at age 24 months.
Associations of genotypes with the PCA scores, cluster
membership and anaemia
The associations of the different genotypes were investi-
gated in the five oxidative pathway genes with the two
PCA scores, with the cluster membership and with an-
aemia. No significant association was found with PCA1,
however GCLC RS10948751 was significantly associated
with PCA2 (Figure 4). No genotypes were associated
with the cluster membership except for RS3594 in GSR
(Figure 5A). The CC homozygotes had a significantly
higher percentage of Group B compared with children
with CA or AA genotypes (52.6% vs. 36.5%, p = 0.037)
(Figure 5A). The CC homozygotes also had a higherPr
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http://www.malariajournal.com/content/13/1/134percentage of anaemia relative to children with CA or
AA genotypes, but this difference was not statistically
significant (9.3% vs. 2.2%, p = 0.11) (Figure 5B).
Mixed linear regression model analyses on the
associations of genotypes and AOPP plasma levels
Using a mixed linear regression model, the associations
of genotypes were investigated with the AOPP plasma
levels measured at the five time points. The model
showed that the variables age (the five time points) and
anaemia (presence/absence) were significantly associated
with the plasma AOPP levels, with the presence of an-
aemia being associated with higher AOPP levels and age
associated with decreased AOPP. After adjusting for age
and presence/absence of anaemia the SNPs GCLC
RS10948751 and HMOX1 RS17885925 were also signifi-
cantly associated with the levels of AOPP (p = 0.030 and
p = 0.027, respectively). Figure 6 shows the levels of
AOPP (adjusted for age and anaemia) for the different
genotypes of these two SNPs. In the regression modelAA
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Figure 4 Associations of the GCLC RS10948751 genotype with
the PCA scores (mean and 95% confidence intervals); Analysis
of variance was employed for data analysis.analysis, the effects of gender, maternal malaria infection
and intervention were not significantly associated to the
AOPP levels.
Discussion
This is the first study to investigate the complex rela-
tionships between oxidative stress pathway genes, the
oxidative stress biomarker AOPP, anaemia and clinicalG
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dren. The findings in this study are: (1) Plasma AOPP is
a valuable oxidative stress biomarker of anaemia and
clinical malaria infection in children two years old living
in a malaria endemic area; (2) Preceding levels of AOPP
predict to some extent the development of anaemia in
children two years old; and (3) Variants in GCLC, GSR
and HMOX1 genes are associated with the host oxidative
stress status, which was evidenced by their associations
with AOPP levels. This study provides valuable data to ex-
plain the complex oxidative stress phenomena in children
regarding anaemia and clinical malaria infection.
AOPP are biomarkers for oxidative stress, and were
first detected in the plasma of chronic uraemic patients
[20]. In addition, AOPP have been investigated for asso-
ciations with many other chronic conditions such as al-
lergic rhinitis [31], severe obesity [32,33], inflammatory
bowel disease [34], atherosclerosis [35], coronary artery
disease [36], ulcerative colitis [37], and many others
[38-42]. There is evidence that AOPP are both bio-
markers of an imbalance between pro-oxidants and anti-
oxidants, and mediators of inflammation [22,41,43]. In
this study conducted on a longitudinal cohort of chil-
dren enrolled at birth, it has clearly been demonstrated
that children with anaemia at age two years had in-
creased plasma AOPP levels at ages 2.5, 5.5, 10.5, 15 and
24 months. Moreover, based on the levels of AOPP, chil-
dren were stratified into two groups using K-Means
Cluster techniques, and children in Group B (higher
AOPP levels) had more than four times increased risk
for anaemia at age two years relative to children in
Group A (lower AOPP levels). The association observed
between AOPP levels measured just after birth and the
presence of anaemia at age two years suggests that the
early oxidative stress burden predicts the later develop-
ment of anaemia in young children living in a malaria
endemic area. Children with clinical malaria infection atage two years had concurrently higher levels of AOPP,
which may have resulted from the simultaneous inter-
dependence of oxidative stress with malaria infection. In
addition, clinical malaria infection at age two years was
associated with a higher score for PCA2 that was posi-
tively correlated with AOPP levels at age 24 months,
and negatively correlated with AOPP levels at ages 2.5
and 5.5 months. Since PCA2 only explained 20% of the
variation of AOPP levels at the five time points, there
was insufficient evidence that the early levels of AOPP
at 2.5 and 5.5 months, possibly related to early malaria
exposure, were associated with a protective effect against
later clinical malaria. Moreover, the raw analysis on the
association between AOPP levels at 2.5 and 5.5 months
did not support this relationship. Interestingly however,
the RBC oxidative stress marker 4-hydroxynonenal-
conjugates, was recently reported to be associated with
malaria susceptibility in young children [27]. Therefore,
more studies, using AOPP as biomarkers are indicated
to further elucidate the relationship between early oxida-
tive burden, and later susceptibility to clinical malaria.
However, the data in the present study showed that
AOPP levels were an early predictor for anaemia and a
simultaneous oxidative stress biomarker of clinical mal-
aria in two years old children.
The main goal of this study was to investigate the as-
sociations of 12 functionally important polymorphisms
in five oxidative stress pathway genes with plasma AOPP
levels. One polymorphism which violated the Hardy-
Weinberg equilibrium and one redundant polymorphism
were excluded, thus only 10 were included in the ana-
lyses. To circumvent multiple tests, the relationships
were examined of these 10 polymorphisms with the two
PCA scores derived from the AOPP levels at the five
time points. The GCLC SNP RS10948751 was associated
with PCA2, and the further mixed linear regression
model analysis confirmed the association of this SNP
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gating associations of variations of the GCLC gene with
susceptibility to malaria or with the biomarker AOPP.
However, a few studies have reported that the SNP -129
C/T and the TNR (GAG trinucleotide repeat) poly-
morphism in the GCLC gene are associated with several
clinical phenotypes such as type 1 diabetes [44], chronic
beryllium disease [45], depression [46] and lung function
and growth [47]. This study provides new evidence
that sequence variations of the glutamate cysteine ligase
gene are related to the anti-oxidative stress-response.
Consistent with a previous study [45] the polymorphism-
associated variation in the AOPP levels may increase
pro-inflammatory phagocyte activity thus inducing lipid-
peroxidation activity with subsequent oxidative plasma
and RBC membrane modifications [48], decreased RBC
filterability [3], enhanced RBC phagocytosis [49] and de-
fective erythropoiesis [48]. These cellular processes may
partly explain the associations found between polymor-
phisms in this gene and anaemia. In addition, one variant
in the GSR gene (RS3594) was associated with cluster
membership based on AOPP levels measured longitudin-
ally during the first two years of life. Polymorphisms in
the GSR gene have been associated with postmenopausal
bone mineral density values [17] and COPD [11]. This
study provides evidence for the functional importance of
polymorphisms in the GSR gene in relation to oxidative
stress in an inflammatory disease. In case of an association
between the GSR polymorphisms and a low anti-oxidant
glutathione reducing activity, increased AOPP values
would be the direct consequence of any inflammatory re-
sponse or oxidation by the malaria parasite growing in
RBCs. Indeed, P-falciparum-parasitized RBCs with these
GSR phenotypes were reported to show increased in-vitro
phagocytosis rates due to membrane oxidations [50].
Similar mechanisms might play a role in vivo and explain
the association of the GSR polymorphism with anaemia.
A few studies have investigated the associations of
the HMOX1 gene polymorphisms with malaria suscepti-
bility in humans [16,19,51]. A microsatellite polymorph-
ism (GT)n was found to be associated with HMOX1
expression and development of symptomatic or severe mal-
aria [16,19]. The present study found that the HMOX1
RS17885925 polymorphism was associated with AOPP
levels. However, considering the linkage disequilibrium be-
tween polymorphisms in this gene, the effect of HMOX1
RS17885925 on the AOPP levels may be attributed to other
intragenic variants [16,19].
The main limitation of this study was that the longitu-
dinal cohort had a small sample size (less than 300 chil-
dren at age two years). As the subjects were recruited
from a general African community, the prevalence of an-
aemia and clinical malaria infection was less than 12%,
with only 23 anaemic children and 32 children withclinical malaria infection at age two years. This study,
therefore, did not have sufficient statistical power to in-
vestigate the associations of the different genotypes with
the anaemia and clinical malaria infection phenotypes.
However, AOPP plasma levels were longitudinally mea-
sured, and this has provided a comprehensive assess-
ment of the children’s oxidative status and allowed a
systematic examination of the complex interrelationships
between AOPP plasma levels, polymorphisms in several
oxidative stress pathway genes and anaemia and clinical
malaria infection in the longitudinal cohort.
In conclusion, the present study has identified several
polymorphisms in GCLC, GSR and HMOX1 genes that
are associated with oxidative stress status in the blood
plasma of two-year old children from a malaria endemic
region. In addition, plasma AOPP is an oxidative stress
marker for clinical malaria in these children and that
AOPP levels are predictive for anaemia.
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